Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tolperisone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 58Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Neurana concludes subject enrolment in trial of muscle spasm therapy
    Neurana concludes subject enrolment in trial of muscle spasm therapy

    30 Nov 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/neurana-enrolment-muscle-spasm/

    CLINICALTRIALSARENA
    30 Nov 2021
    Share Share
    DCGI asks to restrict use of tolperisone FDC to post stroke spasticity only
    DCGI asks to restrict use of tolperisone FDC to post stroke spasticity only

    03 Sep 2021

    // PHARMABIZ

    http://www.pharmabiz.com/NewsDetails.aspx?aid=142291&sid=1

    PHARMABIZ
    03 Sep 2021
    Share Share
    Neurana Pharmaceuticals to Present at Napa Pain Conference and PAIN Week
    Neurana Pharmaceuticals to Present at Napa Pain Conference and PAIN Week

    30 Aug 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neurana-pharmaceuticals-to-present-at-napa-pain-conference-and-pain-week-301364884.html

    PRNEWSWIRE
    30 Aug 2021
    Share Share
    Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study
    Neurana Pharmaceuticals Announces 50% Enrollment in Phase 3, RESUME-1 Study

    07 Jun 2021

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neurana-pharmaceuticals-announces-50-enrollment-in-phase-3-resume-1-study-301305651.html

    PRNEWSWIRE
    07 Jun 2021
    Share Share
    Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS
    Neurana Pharmaceuticals Announces Top-Line Results from Tolperisone Phase 1 CNS

    08 Dec 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/neurana-pharmaceuticals-announces-top-line-results-from-tolperisone-phase-1-cns-effects-study-301188774.html

    PRNEWSWIRE
    08 Dec 2020
    Share Share
    Neurana Pharma announces positive results from phase 2 STAR study of tolperisone
    Neurana Pharma announces positive results from phase 2 STAR study of tolperisone

    25 Sep 2019

    // PHARMABIZ

    http://pharmabiz.com/NewsDetails.aspx?aid=118372&sid=2

    PHARMABIZ
    25 Sep 2019
    Share Share